AstraZeneca’s Imfinzi Approved by FDA for BCG-Naïve Non-Muscle-Invasive Bladder Cancer
Editor’s Take: This cancer drug from a major pharma company continues to show efficacy in varied indications. AstraZeneca’s Imfinzi (durvalumab), combined with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, gained U.S. FDA approval for …